Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 trial designed to evaluate its anti-TIGIT therapy domvanalimab in gastric and ...

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ: GILD), due to futility. • ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

Google has rolled out its December security update. The update patches 107 security vulnerabilities. Two of the security flaws may have already been exploited. Constantly keeping all your hardware and ...

Google makes one big Android release a year — until now. This week, it released Android 16 QPR2. In some ways it’s a minor update, but one that means there should be greater flexibility and, therefore ...

Google announced on Tuesday that it is releasing a slew of Android 16 updates, along with new general Android and accessibility features. The rollout of the new Android 16 features, which are first ...

The popular open-source SmartTube YouTube client for Android TV was compromised after an attacker gained access to the developer's signing keys, leading to a malicious update being pushed to users.

Google has suddenly confirmed Android is under attack, rushing out fixes for two vulnerabilities “that could lead to remote denial of service with no additional execution privileges needed.” ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late ...

Arcus Biosciences boasts a diverse, promising pipeline with key candidates like domvanalimab, casdatifan, and quemliclustat advancing in pivotal trials. Recent data from RCUS's EDGE-Gastric trial show ...

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators ...